Terminal Access

Unlimited access to the most powerful analytical tools in finance.

Bloomberg Fair Value
20M Securities
50Y History
10Y Estimates
8.000+ News Daily
Subscribe for $2
Overview
Profile

Antares Pharma stock

ATRS
US0366421065
903128

Price

5.59
Today +/-
+0
Today %
+0 %

Antares Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Antares Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Antares Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Antares Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Antares Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Antares Pharma Stock Price History

DateAntares Pharma Price
5/24/20225.59 undefined
5/23/20225.59 undefined

Antares Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Antares Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Antares Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Antares Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Antares Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Antares Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Antares Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Antares Pharma’s growth potential.

Antares Pharma Revenue, EBIT and net profit per share

DateAntares Pharma RevenueAntares Pharma EBITAntares Pharma Net Income
2026e420.84 M undefined332.52 M undefined264.12 M undefined
2025e353.84 M undefined163.66 M undefined123.5 M undefined
2024e303.46 M undefined82.17 M undefined58.9 M undefined
2023e260.61 M undefined52.06 M undefined38.05 M undefined
2022e214.62 M undefined20.95 M undefined13.94 M undefined
2021183.98 M undefined27.34 M undefined46.29 M undefined
2020149.6 M undefined13.6 M undefined56.2 M undefined
2019123.9 M undefined1 M undefined-2 M undefined
201863.6 M undefined-16.6 M undefined-6.5 M undefined
201754.5 M undefined-16.5 M undefined-16.7 M undefined
201652.2 M undefined-24.1 M undefined-24.3 M undefined
201545.7 M undefined-20.5 M undefined-20.7 M undefined
201426.5 M undefined-35.1 M undefined-35.2 M undefined
201320.6 M undefined-20.9 M undefined-20.5 M undefined
201222.6 M undefined-11.5 M undefined-11.4 M undefined
201116.5 M undefined-4.4 M undefined-4.4 M undefined
201012.8 M undefined-6 M undefined-6.1 M undefined
20098.3 M undefined-9.7 M undefined-10.3 M undefined
20085.7 M undefined-12.2 M undefined-12.7 M undefined
20077.9 M undefined-6.9 M undefined-8.6 M undefined
20064.3 M undefined-8.2 M undefined-8.1 M undefined
20052.2 M undefined-8.6 M undefined-8.5 M undefined
20042.7 M undefined-8.4 M undefined-8.3 M undefined
20033.8 M undefined-8.7 M undefined-32.8 M undefined
20024 M undefined-8.3 M undefined-11.6 M undefined

Antares Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022e2023e2024e2025e2026e
000010343224758121622202645525463123149183214260303353420
-------33.33-25.00-33.33-100.0075.00-28.5760.0050.0033.3337.50-9.0930.0073.0815.563.8516.6795.2421.1422.8216.9421.5016.5416.5018.98
----100.00-33.3325.0033.3350.0050.0050.0071.4360.0050.0066.6756.2559.0955.0057.6957.7844.2350.0050.7959.3557.7262.8453.7444.2337.9532.5827.38
0000101111125348913111526232732738611500000
0-1-2-4-4-5-9-11-32-8-8-8-8-12-10-6-4-11-20-35-20-24-16-6-25646133858123264
--100.00100.00-25.0080.0022.22190.91-75.00---50.00-16.67-40.00-33.33175.0081.8275.00-42.8620.00-33.33-62.50-66.67-2,900.00-17.86-71.74192.3152.63112.07114.63
1.41.41.41.44.34.38.59.615.136.341.551.659.667.273.583.297110.2126.9130.5146.6155156.1157.4162.6170.2174.7300000
--------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Antares Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Antares Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (k)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021
                                                 
0.30.50.70.220.31.99.62.77.726.113.113.69.831.473.263.14047.927.731.627.945.753.167.16
00000.50.20.50.30.20.90.51.32.52.23.631.45.49.210.812.429.443.350.464.73
0000.40.40000.100000000000000026.31
00000.70.60.20.100.10.10.20.30.30.916.55.95.75.39.311.41618.211.54
00000.10.50.10.10.30.20.60.30.20.20.40.51.72.33.31.42.32.63.44.94.53
0.30.50.70.63.71.62.710.13.38.927.314.916.612.536.377.772.753.666.145.255.671.3108.4126.6174.27
0.20.90.80.81.91.50.80.60.50.40.51.80.30.30.63.6710.814.817.916.214.921.428.629.79
00000000000000312600000000
0005.1000000000000000000000
0.10.20.20.34.42.21.20.90.90.80.60.60.70.811.11.32.92.421.40.80.57.717.88
0.60.40.30.11.21.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.11.09
00000.10.10.10.40.30.40.81.50.40.4000.90.30.20.10.10.11.348.534.47
0.91.51.36.37.64.93.232.82.7352.52.65.717.816.315.118.521.118.816.924.385.983.23
1.2226.911.36.55.913.16.111.630.319.919.115.14295.58968.784.666.374.488.2132.7212.5257.5
                                                 
0.40.70.70.70.10.10.20.40.40.50.70.70.80.811.31.31.31.51.61.61.61.71.71.7
1.11.11.11.237.542.477.894.595.3106.8125.4127.9139.6143.3172.1238.7243.4249295.3297.8303314.9332.4340.8351.08
-3.8-8-12-17.3-29.5-41.2-74.1-82.6-91.1-99.3-107.9-120.6-130.9-137-141.4-152.8-173.3-208.4-229.1-253.4-270.3-276.8-278.8-222.6-176.34
0-0.30.91.5-0.6-0.6-3.5-4.1-3.8-2.9-0.7-0.8-0.7-0.6-0.6-0.7-0.7-0.7-0.7-0.7-0.7-0.7-0.7-0.7-0.69
0000000000000000000000000
-2.3-6.5-9.3-13.97.50.70.48.20.85.117.57.28.86.531.186.570.741.26745.333.63954.6119.2175.75
0.30.50.50.80.60.60.30.50.90.80.82.11.91.82.12.96.410.15.27.9611.112.916.217.06
0.10.10.30.21.11.50.80.60.81.11.510.51.31.31.92.31.632.72.53.714.917.227.11
00.50.621.81.510.50.6111.65.93.66.53.27.612.68.69.37.39.34.613.613.26
000007000000000000000000000
0.10.10.10.10.10.100002.12.70000000003016.21.5
0.51.21.53.13.64.42.11.62.32.95.47.48.36.79.9816.324.316.819.915.827.132.463.258.93
3.37.910.117.70.1000004.72.20000000024.922.140.424.718.24
0000000000000000000000000
000001.23.63.33.13.62.63.12.11.80.811.93.30.71.20.205.45.54.58
3.37.910.117.70.11.23.63.33.13.67.35.32.11.80.811.93.30.71.225.122.145.830.222.82
3.89.111.620.83.75.65.74.95.46.512.712.710.48.510.7918.227.617.521.140.949.278.293.481.75
1.52.62.36.911.26.36.113.16.211.630.219.919.21541.895.588.968.884.566.474.588.2132.8212.6257.5
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Antares Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Antares Pharma's financial health and stability.

Assets

Antares Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Antares Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Antares Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Antares Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (k)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021
-2-4-3-5-9-11-32-8-8-8-8-12-10-6-4-11-20-35-20-24-16-6-25646
0000100000000000011122223
00000000000000000000000-4613
0001-111000-103-10-121-133-11-6-1801
0000132610141111226433-679-29
0000000000000000000000332
0000000000000000000000001,000
-1-3-2-3-8-5-3-7-7-6-5-10-5-6-1-10-14-26-28-15-23-17-102136
00000000000-1000-3-3-5-6-5-10-2-14-20
000-1000-87-5-111400-15-21018-159-411-208-3
000-1000-77-4-111600-15-18224-915-312-172216
0000000000000000000000000
14341410006-2-50000000250150-20
0000100315011171102276423420171215
243411451501123052276422420267250-19
-----------------------1.00-1.00-5.00
0000000000000000000000000
00001-11010730-3932-13-5-1-5-11-42912
0000000000000000000000000
0000000000000000000000000

Antares Pharma stock margins

The Antares Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Antares Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Antares Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Antares Pharma's sales revenue. A higher gross margin percentage indicates that the Antares Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Antares Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Antares Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Antares Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Antares Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Antares Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Antares Pharma Margin History

Antares Pharma Gross marginAntares Pharma Profit marginAntares Pharma EBIT marginAntares Pharma Profit margin
2026e62.89 %79.01 %62.76 %
2025e62.89 %46.25 %34.9 %
2024e62.89 %27.08 %19.41 %
2023e62.89 %19.98 %14.6 %
2022e62.89 %9.76 %6.5 %
202162.89 %14.86 %25.16 %
202057.82 %9.09 %37.57 %
201959.24 %0.81 %-1.61 %
201851.1 %-26.1 %-10.22 %
201749.54 %-30.28 %-30.64 %
201644.83 %-46.17 %-46.55 %
201557.33 %-44.86 %-45.3 %
201457.74 %-132.45 %-132.83 %
201355.34 %-101.46 %-99.51 %
201257.96 %-50.88 %-50.44 %
201158.79 %-26.67 %-26.67 %
201066.41 %-46.88 %-47.66 %
200950.6 %-116.87 %-124.1 %
200863.16 %-214.04 %-222.81 %
200774.68 %-87.34 %-108.86 %
200662.79 %-190.7 %-188.37 %
200550 %-390.91 %-386.36 %
200451.85 %-311.11 %-307.41 %
200347.37 %-228.95 %-863.16 %
200235 %-207.5 %-290 %

Antares Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Antares Pharma earnings per share therefore indicates how much revenue Antares Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Antares Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Antares Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Antares Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Antares Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Antares Pharma Revenue, EBIT and net profit per share

DateAntares Pharma Sales per ShareAntares Pharma EBIT per shareAntares Pharma Earnings per Share
2026e2.46 undefined0 undefined1.55 undefined
2025e2.07 undefined0 undefined0.72 undefined
2024e1.78 undefined0 undefined0.34 undefined
2023e1.53 undefined0 undefined0.22 undefined
2022e1.26 undefined0 undefined0.08 undefined
20211.05 undefined0.16 undefined0.26 undefined
20200.88 undefined0.08 undefined0.33 undefined
20190.76 undefined0.01 undefined-0.01 undefined
20180.4 undefined-0.11 undefined-0.04 undefined
20170.35 undefined-0.11 undefined-0.11 undefined
20160.34 undefined-0.16 undefined-0.16 undefined
20150.31 undefined-0.14 undefined-0.14 undefined
20140.2 undefined-0.27 undefined-0.27 undefined
20130.16 undefined-0.16 undefined-0.16 undefined
20120.21 undefined-0.1 undefined-0.1 undefined
20110.17 undefined-0.05 undefined-0.05 undefined
20100.15 undefined-0.07 undefined-0.07 undefined
20090.11 undefined-0.13 undefined-0.14 undefined
20080.08 undefined-0.18 undefined-0.19 undefined
20070.13 undefined-0.12 undefined-0.14 undefined
20060.08 undefined-0.16 undefined-0.16 undefined
20050.05 undefined-0.21 undefined-0.2 undefined
20040.07 undefined-0.23 undefined-0.23 undefined
20030.25 undefined-0.58 undefined-2.17 undefined
20020.42 undefined-0.86 undefined-1.21 undefined

Antares Pharma business model

The company Antares Pharma Inc was founded in 1979 in Minneapolis, USA. It has since become a successful company in the field of drug development and marketing. The company has been listed on the NASDAQ since 2006. Antares Pharma is a pharmaceutical company specializing in the development of injectable medications. Their business model is to develop innovative injectable products that meet the needs of patients and doctors, and are able to improve their therapy experience and increase adherence. The company specializes in three areas: self-injection systems, automatic devices, and pharmaceutical products. The innovation power behind Antares Pharma's development work is an important factor in their success, as well as their skills in market research and marketing. One of the company's main products is the VIBEX Pen, an automatic injection device that can be operated by patients themselves and filled with various therapeutics. The device provides an easy and painless way to administer medications. The company also produces the Makena auto-injector, which is used in pregnancy treatment. Another important product is the QuickShot auto-injector, a proprietary device used by patients to administer hormone preparations, immunomodulators, and various other common therapeutics. Due to its many years of experience and good reputation in the market, Antares Pharma has strong collaborative relationships with the pharmaceutical industry. The company's customers include reputable pharmaceutical companies such as Pfizer, Teva, Merck, and Novartis, who utilize the company's expertise to bring their own products to the market. Antares Pharma is headquartered in Ewing Township, New Jersey, USA. The company employs a variety of research and development experts who are constantly working to develop new medications and therapy approaches. It has strengthened its position as a major player in the pharmaceutical market and its goal remains to continue creating innovative solutions in the industry. Answer: Antares Pharma Inc. is a successful pharmaceutical company specializing in the development and marketing of injectable medications. They are known for their innovative products that improve therapy experiences and increase adherence. With a strong presence in the pharmaceutical market, Antares Pharma collaborates with renowned companies and continues to strive for innovative solutions. Antares Pharma is one of the most popular companies on Eulerpool.com.

Antares Pharma SWOT Analysis

Strengths

Antares Pharma Inc has several strengths that help it stand out in the market. Firstly, the company is known for its innovative drug delivery systems, which offer advantages over conventional methods. These systems allow for more effective and convenient administration of medications, resulting in improved patient experiences. Moreover, Antares Pharma has a strong portfolio of proprietary products, giving it a competitive edge. This diverse product range includes auto-injectors, pen injectors, and topical gels. Additionally, the company has established strategic partnerships with major pharmaceutical companies, facilitating distribution and market penetration. This expansive network enhances Antares Pharma's market position and increases its financial stability.

Weaknesses

Despite its strengths, Antares Pharma Inc also faces some weaknesses that require attention. One of the main areas of concern is its reliance on a limited number of distribution partners. This dependency exposes the company to potential risks, such as changes in partnership terms or shifts in market dynamics. Furthermore, Antares Pharma operates in a highly regulated industry, which introduces challenges related to compliance and governmental approvals. This can lead to delays in product launches and hinder the company's ability to promptly respond to market demands. Addressing these weaknesses will be crucial for Antares Pharma's sustained growth and success.

Opportunities

Antares Pharma Inc can capitalize on various opportunities to further expand its market presence. The growing demand for alternative drug delivery systems presents a favorable environment for the company to introduce new products and gain market share. Additionally, the increasing focus on precision medicine and personalized therapies creates opportunities for Antares Pharma to develop customized drug delivery solutions. Moreover, expanding its partnerships with pharmaceutical giants and pursuing collaborations with emerging biotech firms can unlock new avenues for growth and diversification. Antares Pharma should closely monitor industry trends and leverage these opportunities to enhance its position in the market.

Threats

Antares Pharma Inc operates in a dynamic and challenging business environment that poses several threats. One of the major threats is intense market competition, as numerous companies are involved in drug delivery systems. This competition could result in pricing pressures, loss of market share, and reduced profitability. Additionally, the company must be prepared for potential regulatory changes that could impact its operations or increase compliance costs. Moreover, fluctuations in raw material prices and supply chain disruptions can negatively affect Antares Pharma's manufacturing processes and overall business performance. Vigilant monitoring of these threats and proactive measures to mitigate them will be essential for the company's long-term sustainability.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Antares Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Antares Pharma historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Antares Pharma shares outstanding

The number of shares was Antares Pharma in 2024 — This indicates how many shares 174.73 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Antares Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Antares Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Antares Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Antares Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Antares Pharma.

Antares Pharma shareholders

%
Name
Stocks
Change
Date
6.35384 % BlackRock Institutional Trust Company, N.A.10,855,659179,19312/31/2021
6.32126 % Rubric Capital Management LP10,800,000800,00012/31/2021
4.94521 % The Vanguard Group, Inc.8,448,987-159,67112/31/2021
2.16297 % Sargent Investment Group, LLC3,695,47562,22512/31/2021
1.95560 % State Street Global Advisors (US)3,341,190-122,48512/31/2021
1.71842 % Geode Capital Management, L.L.C.2,935,96286,97912/31/2021
1.61920 % First Wilshire Securities Management, Inc.2,766,441112,14412/31/2021
1.57244 % Nuveen LLC2,686,553-66,98712/31/2021
1.46228 % CPR Asset Management2,498,337333,86612/31/2021
1.37583 % Silvercrest Asset Management Group LLC2,350,631311,56412/31/2021
1
2
3
4
5
...
10

Antares Pharma Executives and Management Board

Mr. Robert Apple

(55)
Antares Pharma President, Chief Executive Officer, Director (since 2006)
Compensation 3.75 M

Mr. Fred Powell

(60)
Antares Pharma Chief Financial Officer, Executive Vice President
Compensation 1.54 M

Mr. Peter Graham

(54)
Antares Pharma Executive Vice President, Chief Compliance Officer - Human Resources, General Counsel, Corporate Secretary
Compensation 1.53 M

Dr. Leonard Jacob

(72)
Antares Pharma Independent Chairman of the Board
Compensation 327,500

Mr. Anton Gueth

(64)
Antares Pharma Independent Director
Compensation 249,000
1
2
3

Most common questions regarding Antares Pharma

What values and corporate philosophy does Antares Pharma represent?

Antares Pharma Inc represents a set of key values and a strong corporate philosophy. With a focus on innovation, Antares Pharma Inc strives to develop and commercialize pharmaceutical products that improve patients' lives. The company places great importance on quality, aiming to deliver safe and effective treatments. Antares Pharma Inc is committed to fostering a culture of integrity and ethical business practices, ensuring transparency and accountability in all its operations. By prioritizing customer needs and collaboration, Antares Pharma Inc aims to drive shareholder value and establish itself as a leader in the pharmaceutical industry.

In which countries and regions is Antares Pharma primarily present?

Antares Pharma Inc is primarily present in the United States.

What significant milestones has the company Antares Pharma achieved?

Antares Pharma Inc has achieved significant milestones throughout its years of operation. Notably, the company received FDA approval for its flagship product, the Otrexup™ self-injection device, a breakthrough treatment for patients with rheumatoid arthritis and psoriasis. Antares also secured licensing agreements with leading pharmaceutical companies, including Teva and AMAG, further extending its market reach. In addition, the company successfully launched the Makena® subcutaneous auto injector, enhancing patient convenience for a hormone therapy drug used in high-risk pregnancies. Antares Pharma Inc continues to innovate, pursue strategic collaborations, and make remarkable progress in delivering advanced pharmaceutical solutions.

What is the history and background of the company Antares Pharma?

Antares Pharma Inc. is a biopharmaceutical company specializing in the development and commercialization of self-administered parenteral pharmaceutical products. Founded in 1979, Antares Pharma has a rich history of innovation and scientific expertise. The company focuses on advanced drug delivery technologies, including its proprietary needle-free injection system, to improve patient convenience and adherence. With a strong commitment to research and development, Antares Pharma has successfully brought several products to market and licenses its technologies to pharmaceutical partners worldwide. The company's dedication to improving therapeutic outcomes has earned it a reputable position in the pharmaceutical industry.

Who are the main competitors of Antares Pharma in the market?

The main competitors of Antares Pharma Inc in the market are pharmaceutical companies such as Eli Lilly and Company, Novartis AG, Pfizer Inc, Johnson & Johnson, and Amgen Inc.

In which industries is Antares Pharma primarily active?

Antares Pharma Inc is primarily active in the pharmaceutical industry.

What is the business model of Antares Pharma?

Antares Pharma Inc is a pharmaceutical company that specializes in developing and commercializing self-injection drug delivery systems. Their business model focuses on developing innovative technologies that improve the convenience, safety, and efficacy of medication administration. Antares Pharma Inc partners with pharmaceutical companies to enhance their existing products or develop new drug formulations. By providing a range of self-injection systems such as autoinjectors and pen injectors, Antares Pharma Inc aims to improve patient adherence to medication regimens and enhance the overall treatment experience. They prioritize patient-centric solutions to meet the evolving needs of the pharmaceutical industry.

What is the P/E ratio of Antares Pharma 2025?

The Antares Pharma P/E ratio is 7.91.

What is the P/S ratio of Antares Pharma 2025?

The Antares Pharma P/S ratio is 2.76.

What is the Quality Investing of Antares Pharma?

The Quality Investing for Antares Pharma is 5/10.

What is the revenue of Antares Pharma 2025?

The expected Antares Pharma revenue is 353.84 M USD.

How high is the profit of Antares Pharma 2025?

The expected Antares Pharma profit is 123.5 M USD.

What is the business model of Antares Pharma

Antares Pharma Inc is a company that specializes in the development, manufacturing, and marketing of medications, particularly injection solutions. The company has three main business areas: 1. Marketing and manufacturing of medications: Antares Pharma produces and markets primarily injection solutions for various applications. The company has several leading products, including the legal opioid Vergentanib, hormone injections for women, disposable insulin pens, and more. 2. Research and development: Antares Pharma is dedicated to advancing the development of new medications and injection systems. The company heavily invests in research and development to create innovative products that meet the needs of patients. 3. Licensing and partnerships: Antares Pharma also collaborates with other pharmaceutical companies to distribute its products worldwide. The company has partnerships with companies such as Teva, Ferring, and Pfizer to globally market its products. The company offers several leading products: 1. Vergentanib: Vergentanib is a legal opioid for pain relief. The medication is administered through a pre-filled syringe pen manufactured by Antares Pharma. Vergentanib is a widely approved medication available in many countries worldwide. 2. OTREXUP: OTREXUP is a disposable insulin pen for the treatment of diabetes. The insulin pen is made from a special material that reduces the risk of overdosing. 3. QuickShot: QuickShot is a disposable injection system for hormone injections for women. The system is convenient and easy to use, and is utilized by many women around the world. Antares Pharma's business model is based on the development and marketing of injection products for various applications. The company invests in research and development to create innovative products that meet the needs of patients. Antares Pharma also collaborates with partners to market its products worldwide. The company has a strong presence in the market and strives to continue developing and distributing top-quality products to assist patients.

What is the Antares Pharma dividend?

Antares Pharma pays a dividend of 0 USD distributed over payouts per year.

How often does Antares Pharma pay dividends?

The dividend cannot currently be calculated for Antares Pharma or the company does not pay out a dividend.

What is the Antares Pharma ISIN?

The ISIN of Antares Pharma is US0366421065.

What is the Antares Pharma WKN?

The WKN of Antares Pharma is 903128.

What is the Antares Pharma ticker?

The ticker of Antares Pharma is ATRS.

How much dividend does Antares Pharma pay?

Over the past 12 months, Antares Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Antares Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Antares Pharma?

The current dividend yield of Antares Pharma is .

When does Antares Pharma pay dividends?

Antares Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Antares Pharma?

Antares Pharma paid dividends every year for the past 0 years.

What is the dividend of Antares Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Antares Pharma located?

Antares Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Antares Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Antares Pharma from 4/13/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/13/2025.

When did Antares Pharma pay the last dividend?

The last dividend was paid out on 4/13/2025.

What was the dividend of Antares Pharma in the year 2024?

In the year 2024, Antares Pharma distributed 0 USD as dividends.

In which currency does Antares Pharma pay out the dividend?

The dividends of Antares Pharma are distributed in USD.

All fundamentals about Antares Pharma

Our stock analysis for Antares Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Antares Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.